Form 4: Director Sells GRDN Shares in Underwritten Offering

John Ackerman, a Director and 10% owner of Guardian Pharmacy Services, Inc., sold over 1.1 million shares of Class A Common Stock at $29.6825 per share through an underwritten agreement.

Summary

• John Ackerman, a Director and 10% Owner of Guardian Pharmacy Services, Inc. (GRDN), reported a sale of Class A Common Stock.
• The transaction occurred on March 20, 2026, and involved the sale of 1,103,364 shares of Class A Common Stock.
• The shares were sold at a price of $29.6825 per share, totaling approximately $32,730,000.01.
• The sale was executed pursuant to an Underwriting Agreement dated March 18, 2026, involving the Issuer, selling stockholders, and underwriters BofA Securities, Inc. and Jefferies LLC.
• Following the transaction, John Ackerman indirectly beneficially owns 1,035,928 shares through Pharmacy Investors, LLC and 345,123 shares through Cardinal Equity Fund, L.P.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be perceived negatively, the execution under a Rule 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new negative information.

Positives

• The sale was executed at a specific price of $29.6825 per share, providing a clear valuation for the shares at the time of the transaction.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale rather than a reaction to immediate market conditions or new information.

Negatives

• A Director and 10% owner, John Ackerman, sold a significant number of shares (1,103,364 shares) in Guardian Pharmacy Services, Inc.
• Insider selling, even if pre-arranged, can sometimes be interpreted by the market as a signal of reduced confidence in the company's near-term prospects or a desire to lock in gains.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly by significant shareholders like directors and 10% owners, are common events in the market. While often viewed with caution, sales executed under Rule 10b5-1 plans are typically pre-scheduled and less indicative of immediate sentiment shifts compared to opportunistic sales. This transaction reflects a liquidity event for a major shareholder.

Stakeholder Impact

• Shareholders: The sale by a significant insider could lead to short-term negative sentiment, but the pre-arranged nature of the sale under a 10b5-1 plan may mitigate concerns. It also potentially increases the public float if these were previously restricted shares.

Key Dates

Recommendation

The sale by a director and 10% owner, while significant, was executed under a pre-arranged 10b5-1 plan and as part of an underwriting agreement. This suggests a planned liquidity event rather than a reaction to new negative information about Guardian Pharmacy Services, Inc. Without additional context on the company's performance or strategic direction, this transaction alone does not warrant a change from a neutral 'hold' position. Investors should monitor future filings and company performance for further insights.

Keywords

Guardian Pharmacy Services, GRDN, John Ackerman, insider trading, Form 4, stock sale, director, 10% owner, equity, SEC filing, underwriting agreement, 10b5-1 plan